# OnCo record axitinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/axitinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "axitinib" ;
  schema:name "Axitinib"@en ;
  schema:description "Axitinib is a selective VEGF-receptor pill, now given mainly with pembrolizumab or avelumab as first-line kidney cancer treatment."@en ;
  schema:url <https://onco.cc/drugs/axitinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Axitinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q4830631> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Axitinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (VEGFR)" ;
  schema:alternateName "Inlyta" ;
  onco:approval "US 2012: Advanced RCC after one prior systemic therapy", "US 2019: First-line advanced RCC with pembrolizumab or avelumab" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/clear-cell-rcc/>, <https://onco.cc/cancers/adenoid-cystic-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/keynote-426/>, <https://onco.cc/trials/nct07227415/>, <https://onco.cc/trials/nct05805501/>, <https://onco.cc/trials/nct06962787/> .